Disease relevance of strontium

• A retrospective evaluation was performed with records of 128 patients with 146 eyes that underwent applications of strontium-90 after pterygium excisions performed between 1982 and 1988 [1].
• Adjunctive radiotherapy with strontium-90 in the treatment of conjunctival squamous cell carcinoma [2].
• PATIENTS AND METHODS: 83 keloids of 66 patients had been irradiated after excision by a uniform protocol with 4 x 5 Gy (strontium- 90 [(90)Sr] surface applicator) [3].
• Of 140 patients with histologically confirmed squamous cell cancer, 123 were treated with a strontium-90 source, 10 with a radon "ring," and 7 with superficial X ray therapy [2].
• Late toxicities that may be associated with strontium-90 RT were scleromalacia (scleral thinning) in 4 eyes, adhesion of eyelids in 3 eyes, and scleral ulcer in 2 eyes [4].

High impact information on strontium

• Whole-body and thorax gamma-ray measurements, thorax and skeletal actinide measurements, and urinalyses for plutonium-239 and strontium-90 indicated no evidence of radioactivity in excess of that found in the general population [5].
• The tumors were generated spontaneously or induced chemically [with 9,10-dimethyl-1,2-benzanthracene (CAS: 57-97-6)], virally (with murine leukemia virus), or radiogenically (with strontium-90) [6].
• PARTICIPANTS: A total of 16 eyes with subfoveal choroidal neovascular membranes (CNVM) treated with strontium-90 (90Sr)-plaque radiation therapy and 16 fellow eyes of 16 patients were examined [7].
• METHOD: A patient is presented in whom scleral necrosis developed 25 days after a pterygiectomy with bare sclera technique followed by 3000 cGy in 3 weekly, divided doses of strontium 90 [8].
• Mice treated with strontium 90: an animal model deficient in NK cells [9].

Chemical compound and disease context of strontium

• Three-year clinical follow-up after strontium-90/yttrium-90 beta-irradiation for the treatment of in-stent coronary restenosis [10].
• Correlation between Octopus perimetry and fluorescein angiography after strontium-90 plaque brachytherapy for subfoveal exudative age related macular degeneration [11].

Biological context of strontium

• Similar effects on cell proliferation were observed with the Strontium-90 applicator [12].
• The 1945-1965 rise in the percentage of live births below 2500 grams is highly correlated with the amount of strontium-90 in human bone, both peaking in the mid-1960s [13].
• Total body burdens for the 50 reservoir turtles examined in the survey ranged from 164.7-4679.3 Bq for cesium-137 and from 462.6-5098.3 Bq for strontium-90 [14].
• AIM: To analyse local tumour control, radiation related complications, visual acuity, enucleation rate, and survival after brachytherapy of small to medium sized choroidal melanoma (CM) with a high dose rate (HDR) strontium-90 (Sr-90) applicator [15].
• Bone marrow hematopoiesis, measured by total nucleated cell number and viability, megakaryocyte colony-forming cells, and granulocyte-macrophage colony-forming cells, was rapidly ablated in mice by using yttrium 90-free strontium 90 [16].

Anatomical context of strontium

• Strontium-90 in deciduous teeth as a factor in early childhood cancer [17].
• We previously showed that purified strontium 90 produced sustained bone marrow ablation in mice, lowering platelet levels to less than 10% of normal 11 days after administration [18].
• Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002) [19].
• Histologic studies of splenic megakaryocytes after bone marrow ablation with strontium 90 [18].
• The effects of different doses of beta radiation from a strontium-90 source on the proliferation of human Tenon's capsule fibroblasts were studied [20].

Gene context of strontium

• Three patients with a choroidal melanoma, treated with HDR (High Dose Rate) Strontium-90 brachytherapy, underwent an enucleation [21].
• beta Dose distribution during beta irradiation using strontium-90 in ophthalmic practice [22].

Analytical, diagnostic and therapeutic context of strontium

• Vaccination against strontium-90-induced bone tumors [23].
• PURPOSE: We review the results of treatment of small to medium-sized choroidal malignant melanomas after high-dose-rate brachytherapy with a strontium-90 applicator [24].
• RESULTS: 54 tumors in 35 cats were treated with a median dose of 135 Gy of strontium 90 beta irradiation, resulting in local tumor control in 53 of 54 (98%) tumors with a median follow-up time of 783 days after treatment [19].
• Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995 [24].
• To determine the feasibility and safety of an intracoronary beta-radiation device in preventing the recurrence of in-stent restenosis (ISR) after successful angioplasty, we studied 37 patients treated with beta-radiation (30-mm strontium-90 source) after angioplasty [25].

References